Vaccine最新文献

{"title":"Cost-effectiveness of pentavalent meningococcal (MenABCWY) vaccination among adolescents in the United States","authors":"Xiaoyu Dong,&nbsp;Sarah F. Schillie,&nbsp;Lucy Alexandra McNamara,&nbsp;Andrew J. Leidner","doi":"10.1016/j.vaccine.2025.127332","DOIUrl":"10.1016/j.vaccine.2025.127332","url":null,"abstract":"<div><h3>Background</h3><div>Invasive meningococcal disease (IMD) is a severe, acute illness associated with considerable mortality and long-term morbidity. In the United States, meningococcal serogroup A, C, W, and Y (MenACWY) vaccines and serogroup B (MenB) vaccines are used to prevent IMD among adolescents. GlaxoSmithKline has developed a new pentavalent (MenABCWY) vaccine, covering all five serogroups: A, B, C, W, and Y, with licensure in spring 2025. The Advisory Committee on Immunization Practices (ACIP) has been considering three options regarding use of MenABCWY in the context of the existing immunization schedule, which consists of two routine doses of MenACWY, and two doses of MenB under shared clinical decision-making.</div></div><div><h3>Methods</h3><div>This study evaluated the cost-effectiveness of the pentavalent vaccine in adolescents using a population-based model that includes all current 11-year-olds in the United States. We analyzed vaccination strategies over a 19-year period, updating every six months to reflect changes in vaccination coverage, disease incidence and mortality, and costs. We used a lifetime analytic horizon to evaluate outcomes that extend beyond this period, including costs and quality-adjusted life years due to sequelae. The main summary measure was the incremental cost-effectiveness ratio (ICER), calculated as costs per quality-adjusted life year (QALY) gained. Costs were reported in US$2024 and all future values were discounted by 3 % annually.</div></div><div><h3>Results</h3><div>The ICERs varied from being cost-saving when one dose of MenABCWY replaced concurrent administration of MenACWY and MenB, to costing $11,334,294 per QALY gained when two-doses of MenABCWY replaced the two-dose MenACWY regimen. The ICER was most sensitive to the cost of pentavalent vaccine.</div></div><div><h3>Conclusion</h3><div>Using the pentavalent vaccine as an alternative to the simultaneous administration of MenACWY and MenB was cost-saving, but other uses are more costly. Further analyses of other adolescent vaccination schedules are warranted to explore opportunities for cost-effective IMD prevention.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127332"},"PeriodicalIF":4.5,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144240295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 17–21 February 2025","authors":"Philipp Lambach ,&nbsp;Sheetal Silal ,&nbsp;Alyssa N. Sbarra ,&nbsp;Mitsuki Koh ,&nbsp;Rakesh Aggarwal ,&nbsp;Habib Hasan Farooqui ,&nbsp;Stefan Flasche ,&nbsp;Alexandra B. Hogan ,&nbsp;Sun-Young Kim ,&nbsp;Kathy Leung ,&nbsp;William J. Moss ,&nbsp;Allison Portnoy ,&nbsp;Meru Sheel ,&nbsp;Xuan-Yi Wang","doi":"10.1016/j.vaccine.2025.127384","DOIUrl":"10.1016/j.vaccine.2025.127384","url":null,"abstract":"<div><div>The Immunization and Vaccines-related Implementation Research Advisory Committee (IVIR-AC) serves as the World Health Organization's (WHO) key advisory body for independently reviewing research that assesses the impact and value of vaccines, particularly using transmission and economic modeling analyses. During its first semi-annual meeting of 2025, held on 17–21 February and complemented by ad hoc sessions on 5 February, 11 April and 14 April, IVIR-AC provided feedback and recommendations across seven key sessions. This report summarizes the discussions and outcomes of the meeting. Topics covered included immunization research priorities in the WHO Eastern Mediterranean region, multi-model comparisons of typhoid conjugate vaccine schedules, a malaria intervention multi-model comparison, a full value assessment of invasive non-typhoidal <em>Salmonella</em> (iNTS) vaccination, an evaluation of improved influenza vaccines, vaccine impact modeling under the Immunization Agenda 2030 (IA2030) framework, and combination vaccines value assessment.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127384"},"PeriodicalIF":4.5,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144240297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase II/III randomized immunogenicity and safety study of a Brazilian meningococcal serogroup B vaccine in children","authors":"R. Menezes Martins ,&nbsp;M.L.S. Maia ,&nbsp;L.A.B. Camacho ,&nbsp;T.G. Noronha ,&nbsp;V.R. von Doellinger ,&nbsp;A.P. Santos ,&nbsp;E.S. Figueira ,&nbsp;M.L. Leal ,&nbsp;E. Jessouroun","doi":"10.1016/j.vaccine.2025.127363","DOIUrl":"10.1016/j.vaccine.2025.127363","url":null,"abstract":"<div><div>From May 16, 2011 to March 13, 2013, Bio-Manguinhos/Fiocruz conducted a randomized Phase II/III study of a vaccine against <em>N. menigitidis</em> serogroup B, involving 280 children aged between 4 and 11 years, evaluating immunogenicity and safety. This was a dose-escalation study evaluating vaccine candidates containing 12.5 μg, 25 μg, and 50 μg of OMV protein per dose, with dLOS administered at half the concentration of the total protein. The VAMENGOC-BC® vaccine was used as a reference. The vaccination schedule included three doses administered two months apart, followed by a booster dose 6–12 months after the third injection. Bactericidal antibody responses were evaluated using the vaccine strains as primary targets and heterologous strains as secondary targets. All vaccines were well tolerated, and only for fever after the first dose there was a statistically significant difference across comparison groups (<em>p</em> = 0,007). Additionally, unsolicited adverse events and serious adverse events were determined not to be causally related to the vaccines. The candidate vaccines elicited a significant increase in total IgG antibodies against the OMV components of the first prevalent strain and achieved high bactericidal titers against both vaccine strains following the immunization schedule. After the booster dose, all children receiving either the experimental or the reference vaccine were protected against the vaccine strains. For heterologous strains, a protective response was observed based on the similarity of PorA, although the antibody levels remained low. Moreover, the inclusion of detoxified LOS in the experimental formulations underscores the need for further investigation into this molecule as a vaccine component, given that the observed response appears to be concentration dependent. The experimental vaccines showed immunogenicity equivalent to VA-MENGOC-BC® with formulations containing two to four times fewer protein components than the reference vaccine.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127363"},"PeriodicalIF":4.5,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144240402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic mapping review of preclinical and clinical studies of Staphylococcus aureus vaccines","authors":"Rachel Lapeyre ,&nbsp;Nouran Rezk ,&nbsp;Siobhán McClean ,&nbsp;Anne C. Moore","doi":"10.1016/j.vaccine.2025.127333","DOIUrl":"10.1016/j.vaccine.2025.127333","url":null,"abstract":"<div><div><em>Staphylococcus aureus</em> is a pathogen that annually causes more than one million deaths globally. However, despite substantial research, no vaccine for human use has yet been licensed. We conducted a systematic mapping review to evaluate the different pre-clinical and clinical approaches taken in <em>Staphylococcus aureus</em> (<em>S. aureus)</em> vaccine development as well as veterinary vaccines. We examined the testing frequency of different antigens, platforms, routes of immunisation, types of immune response and pre-clinical challenge models. We identified and analysed 358 relevant publications in PubMed. More than 150 antigens were studied in preclinical trials, with alpha-hemolysin (Hla) being the most frequently tested antigen. With respect to pre-clinical challenge models, systemic infections have been studied for the longest period and are the most widely used. Subunit vaccines were the most studied platform; this includes toxoids and polysaccharide antigens. Complete Freund's Adjuvant was the most common adjuvant used and, surprisingly, is still frequently used in recent studies. Antibody titre was the most frequently assessed vaccine-induced immune parameter and opsonophagocytosis has been the most common functional humoral readout. This review identifies trends for the development of a <em>S. aureus</em> vaccine, and highlights the lessons learned from past failures and the opportunities for current and future development. This quantitative evidence identifies predominant themes in the <em>S. aureus</em> vaccine field and therefore contributes to highlighting less explored gaps and potential new avenues of research in ongoing efforts to developing urgently needed, effective <em>S. aureus</em> vaccines.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127333"},"PeriodicalIF":4.5,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144240404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strategies to improve interprofessional communication regarding maternal and infant RSV immunization","authors":"Tamima Hossain ,&nbsp;Honora Quinn Burnett ,&nbsp;Sarah Schaffer DeRoo","doi":"10.1016/j.vaccine.2025.127366","DOIUrl":"10.1016/j.vaccine.2025.127366","url":null,"abstract":"","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127366"},"PeriodicalIF":4.5,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144231904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychometric validation of the COVID-19 vaccine hesitancy scale for primary and booster doses among university students: A cross-sectional study","authors":"Bara’ Abdallah AlShurman ,&nbsp;Shannon E. Majowicz ,&nbsp;Kelly Grindrod ,&nbsp;Joslin Goh ,&nbsp;Zahid Ahmad Butt","doi":"10.1016/j.vaccine.2025.127368","DOIUrl":"10.1016/j.vaccine.2025.127368","url":null,"abstract":"<div><h3>Background</h3><div>Vaccine hesitancy (VH) continues to impede COVID-19 vaccine coverage. Booster dose uptake lags behind primary dose uptake, especially among younger adults. Unlike most studies that focus on initial stages of VH, the aim of this study was to validate the COVID-19 Vaccine Hesitancy Scale (CVHS) for both primary and booster doses among University of Waterloo (UW) students.</div></div><div><h3>Methods</h3><div>An online survey was conducted among UW students in Ontario, Canada, between March and May 2024. The CVHS items were adapted for primary and booster doses. Exploratory (EFA) and confirmatory factor analyses (CFA) assessed the factor structure and model fit. Reliability was evaluated using Cronbach's alpha and composite reliability (CR). Convergent and discriminant validity were assessed through average variance extracted (AVE). Significant differences between primary and booster dose hesitancy were determined via 95 % Confidence Interval.</div></div><div><h3>Results</h3><div>A total of 4453 students participated. Respondents were predominantly female (57.2 %), aged 18–22 years (84.0 %), and undergraduates (94.8 %). EFA and CFA confirmed a three-factor structure for both primary and booster dose scales. Both scales had high reliability (Cronbach's alpha &gt;0.60, CR &gt;0.7). CFA results indicated a good model fit (Comparative Fit Index = 0.94; Root Mean Square Error of Approximation = 0.07), and demonstrated adequate convergent, discriminant, and criterion validity. Known-group validity was supported by significant differences in VH scores across gender and academic level, with men and undergraduate students reporting higher hesitancy than women and graduate students (<em>p</em> &lt; 0.001). VH was higher for booster doses (33.4 %) than primary doses (19.3 %) with more students delaying (32.1 %) or refusing boosters (29.3 %) than delaying (11.5 %) or refusing (6.2 %) primary doses.</div></div><div><h3>Conclusion</h3><div>Our adapted scales performed well psychometrically to measure VH across different COVID-19 vaccine phases. These scales can help in identifying key barriers of VH to understand shifting trajectories over time, thereby informing targeted interventions to promote vaccination uptake among younger adults.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127368"},"PeriodicalIF":4.5,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144240401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review of currently licensed mucosal COVID-19 vaccines","authors":"Alina Tscherne ,&nbsp;Florian Krammer","doi":"10.1016/j.vaccine.2025.127356","DOIUrl":"10.1016/j.vaccine.2025.127356","url":null,"abstract":"<div><div>The rapid development and deployment of injectable coronavirus disease 2019 (COVID-19) vaccines - in combination with non-pharmaceutical interventions and development of treatment options - significantly contributed to a decrease in both infection and mortality rates during the pandemic and saved millions of lives. However, injectable vaccines do not robustly and consistently induce a mucosal immune response, which is considered a key factor to prevent infection with and transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Hence, a tremendous effort is being made globally to develop next generation COVID-19 vaccines, which are capable of inducing a robust mucosal immune response in addition to a strong systemic cellular and humoral immune response. Mucosal COVID-19 vaccines have been evaluated successfully in preclinical and clinical trials, in which protection against SARS-CoV-2 infection has been demonstrated. This protective efficacy was associated with the upregulation of secretory IgA antibodies and the maturation of tissue-resident memory cells in the respiratory tract, which, together with an induced systemic immune response, significantly reduced viral replication and transmission in animal models. However, only five active mucosal vaccines (plus one ‘passive’ vaccine) have received approval for human use and robust data on their efficacy in inducing mucosal immune responses in humans and in blocking infection and transmission are missing. This highlights the importance of expanded research in this field. In this review, we aim to summarize what is known about these currently licensed vaccines, with an emphasis on the key findings obtained in both preclinical and clinical studies.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127356"},"PeriodicalIF":4.5,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144231905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between COVID-19 vaccination and first healthcare utilization for chronic obstructive pulmonary disease: A nationwide population-based cohort study","authors":"Sang Hyuk Kim ,&nbsp;Seung-Hun You ,&nbsp;Ju Won Lee ,&nbsp;Eunji Kim ,&nbsp;Youlim Kim ,&nbsp;Hyun Lee ,&nbsp;Sun-Young Jung ,&nbsp;Ji-Yong Moon","doi":"10.1016/j.vaccine.2025.127367","DOIUrl":"10.1016/j.vaccine.2025.127367","url":null,"abstract":"<div><h3>Background</h3><div>Uncertainties about the impact of coronavirus disease 2019 (COVID-19) vaccination on chronic obstructive pulmonary disease (COPD) have been increasing. Thus, this study aimed to investigate the association between COVID-19 vaccination and COPD.</div></div><div><h3>Methods</h3><div>We conducted a cohort study using COVID-19 immunization registry data. The exposure was COVID-19 vaccination status, and the outcome was first healthcare utilization for COPD. Cox proportional hazards models were used to assess the risk of first healthcare utilization for COPD.</div></div><div><h3>Results</h3><div>Of the 27,595,469 individuals, 93.9 % had received COVID-19 vaccination. The risk of first healthcare utilization for COPD was significantly lower in vaccinated participants than in unvaccinated participants (hazard ratio [HR] = 0.46, 95 % confidence interval [CI] = 0.46–0.47). The decreased risk was more evident for first emergency room visits or hospitalizations for COPD (HR = 0.24, 95 % CI = 0.24–0.25). In the subgroup analysis, the decreased risk of first healthcare utilization for COPD was less significant in participants with frequent healthcare utilization, including the elderly, women, medical aid recipients, and those with comorbidities, than their counterparts. Of these, the smaller magnitude of the inverse association was observed in the pulmonary tuberculosis and asthma group. Regarding vaccination subtypes, the reduction was more prominent among those with a single vaccination (HR = 0.27, 95 % CI = 0.26–0.29) and mRNA recipients (HR = 0.35, 95 % CI = 0.35–0.36).</div></div><div><h3>Conclusions</h3><div>COVID-19 vaccination is associated with a decreased risk of first healthcare utilization for COPD, particularly concerning mRNA vaccine and emergency room visits or hospitalizations. Among frequent healthcare utilizers, the effect of vaccination is more pronounced in individuals with pulmonary tuberculosis or asthma than in those without pulmonary tuberculosis or asthma.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127367"},"PeriodicalIF":4.5,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144222190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human adenovirus penton dodecahedron nanoparticles induce an enhanced neutralizing antibody response in mouse model","authors":"Liling Zhou ,&nbsp;Yujie Yang ,&nbsp;Chuncong Mo ,&nbsp;Yuhui Zhu ,&nbsp;Ye Fan ,&nbsp;Wenkuan Liu ,&nbsp;Xiao Li ,&nbsp;Rong Zhou ,&nbsp;Xingui Tian","doi":"10.1016/j.vaccine.2025.127380","DOIUrl":"10.1016/j.vaccine.2025.127380","url":null,"abstract":"<div><div>Vaccination is the most effective way to prevent infectious diseases and control outbreaks, and nanoparticles are highly suitable platforms for protein-based vaccines. Human adenovirus type 7 (Ad7) is one of the main pathogens causing severe pneumonia. A safe and effective vaccine against Ad7 infection is urgently needed. Penton-dodecahedron (Pt-Dd) nanoparticles, can be generated by the spontaneous assembly of the penton during the replication cycle of human adenovirus type 3. Adenovirus type 3 Pt-Dd has been studied as drug delivery vehicles. However, little attention has been paid to whether Pt-Dd can elicit a neutralizing antibody response, serve as an adenovirus vaccine candidate. In this study, we designed a Pt-Dd nanoparticle vaccine by co-expressing the penton base and fiber of Ad7 with the insect cell-baculovirus expression system and evaluated its immunogenicity in mice. The results showed that Ad7 Pt-Dd induced high titers of neutralizing antibody production and triggered a strong cellular immune response. In contrast, Ad7 penton base nanoparticles induced low levels of neutralizing antibody responses and strong cellular immune responses. Ad7 Pt-Dd immunization provided immune protection against Ad7 pneumonia in humanized desmoglein-2 receptor transgenic mice. In summary, Ad7 Pt-Dd nanoparticles induce protective humoral and cellular immune responses and can be used as a vaccine candidate against Ad7 infection. This study enhances our comprehension of human adenovirus neutralizing antigens and broadens the spectrum of applications for adenovirus Pt-Dd nanoparticles.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127380"},"PeriodicalIF":4.5,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144222186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing faith and interfaith based facilitators and reducing related barriers to enhance vaccine acceptance: a qualitative study","authors":"Sara Garfield,&nbsp;Farzana Ali,&nbsp;Sudaxshina Murdan","doi":"10.1016/j.vaccine.2025.127348","DOIUrl":"10.1016/j.vaccine.2025.127348","url":null,"abstract":"<div><div>The relationship between faith and vaccine hesitancy is complex and the need to consider religion and engage with faith leaders has been recognised. However, most faith-based interventions in this field have been conducted on individual faiths, in isolation from other faiths, and have not explored the potential for active collaboration among faith-based groups. To address this gap, we conducted a study that aimed to inform the development of interfaith-based interventions to enhance vaccine acceptance. We conducted six focus groups, two semi-structured interviews and an interfaith co-design workshop, in community, online and University settings in London. Participants were from the Islamic, Christian, Jewish, Hindu and Sikh faiths. Interviews, focus groups and the workshop were transcribed verbatim and analysed using inductive reflective thematic analysis. We found that although there were some potential barriers to vaccine uptake due to religious beliefs, religion was a facilitator of vaccine uptake via the emphasis on protecting oneself and one's community and saving lives. However, embedded barriers in religious communities were related to mistrust, feelings of stigma and blame and tokenistic engagement. Key required interventions identified by participants were (i) training faith leaders to enable them to provide tailored messages to their communities, (ii) involving faith-based communities early in the process to enable them to feel included, rather than only approaching them once they were deemed hesitant, and (iii) vaccination messages delivered by groups of leaders from different faiths, so that they are all ‘singing from the same hymn sheet’. Interventions to increase vaccine uptake among faith groups need to focus on building trust and inclusivity, rather than on religious beliefs.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127348"},"PeriodicalIF":4.5,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144222142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}